Notch | $15,000,000 | (Oct 2, 2025)
Clarifeye | $4,693,900 | (Oct 2, 2025)
Ankored | $4,000,000 | (Oct 2, 2025)
Ultromics
United Kingdom
- Oxford, Oxfordshire
- 31/07/2025
- Series C
- $55,000,000
Ultromics pioneers precision heart failure detection. Our groundbreaking platform, EchoGo®, is revolutionizing the diagnosis of heart failure using artificial intelligence and cardiac ultrasound. Our technology empowers clinicians to make precise, efficient, and accurate assessments, drawing from the largest known heart disease dataset in echocardiography. We target challenging cardiac diseases, starting with HFpEF, to support timely diagnosis and early intervention. In collaboration with the Mayo Clinic, Johnson & Johnson, and Pfizer, we are continuously developing innovative diagnostic tools aimed at halting the progression of heart failure.
Learn more: https://www.ultromics.com/.
Follow Ultromics on social media for the latest news, X: https://x.com/ultromics, LinkedIn: https://www.linkedin.com/company/ultromics/.
- Industry Hospital & Health Care
- Website https://www.ultromics.com/
- LinkedIn https://www.linkedin.com/company/ultromics/
Related People
Ross Upton, PhDFounder
United Kingdom -
Greater Oxford Area
Founder, CEO & Chief Scientific Officer, Ultromics
Clinical Researcher, University of Oxford
AI Co-Chair, HeartShare, NIH
Prosper AI | $5,000,000 | (Oct 2, 2025)
Gelt | $13,000,000 | (Oct 2, 2025)
Returnalyze | $6,000,000 | (Oct 2, 2025)
Hupside | $1,700,000 | (Oct 2, 2025)
Athernal Bio | $4,718,630 | (Oct 2, 2025)
Price.com | $12,000,000 | (Oct 2, 2025)
Mondoo | $17,500,000 | (Oct 2, 2025)
SolidCore.ai | $4,000,000 | (Oct 2, 2025)
Phaidra | $50,000,000 | (Oct 2, 2025)